# A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer

> **NCT06115902** · PHASE1 · RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.** · enrollment: 150 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** TQB2102 for injection

## Key facts

- **NCT ID:** NCT06115902
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-17
- **Primary completion:** 2025-12
- **Final completion:** 2026-12
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2023-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06115902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06115902, "A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06115902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*